RESOURCES

Frequently asked questions (FAQs)

About ZILBRYSQ and generalized myasthenia gravis (gMG)

In gMG, pathogenic immunoglobulin G (IgG) autoantibodies attack key proteins, most commonly the acetylcholine receptor (AChR), in the neuromuscular junction (NMJ). This prevents AChR binding, reduces receptor density, and activates the complement system.1

Learn more about complement activation in gMG.

Treatment With ZILBRYSQ

REMS and Safety

Dosing & Administration / Starting ZILBRYSQ

References:

  1. Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7
  2. Mantegazza R, Vanoli F, Frangiamore R, et al. Complement inhibition for the treatment of myasthenia gravis. Immunotargets Ther. 2020;9:317-331. doi:10.2147/ITT.S261414
  3. ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc. 
  4. Howard JF Jr, Bresch S, Farmakidis C, et al. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024;17(3):1-16. doi:10.1177/17562864241243186
  5. Data on file. UCB, Inc.